H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Y-Mabs Therapeutics (NASDAQ:YMAB) Inc on Monday, setting a price target of $52, which is approximately 30.52% above the present share price of $39.84.
Burns expects Y-Mabs Therapeutics Inc to post earnings per share (EPS) of -$0.61 for the second quarter of 2020.
The current consensus among 6 TipRanks analysts is for a Strong Buy rating of shares in Y-Mabs Therapeutics, with an average price target of $41.67.
The analysts price targets range from a high of $44 to a low of $40.
In its latest earnings report, released on 12/31/2019, the company reported a quarterly revenue of $0 and a net profit of -$23.76 million. The company's market cap is $1.58 billion.
According to TipRanks.com, H.C. Wainwright analyst Robert Burns is a 5-star analyst with an average return of 36.1% and a 84.0% success rate.
Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It develops novel antibody therapeutics for oncology targets. The company's services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY.